A digital twin generator for Phase 2 trials can support patient-outcome prediction and, in suitable settings, trial-design and statistical-analysis workflows. One approach uses historical patient data to generate a prognostic score for each enrolled participant, which is then incorporated into a prespecified covariate-adjusted analysis. Published research using Alzheimer’s Phase 2 trial data has evaluated this approach for improving precision and potential sample-size efficiency.

These systems do not automatically replace trial participants or remove the need for a randomised control group. Buyers should assess the model’s relevance to their disease, population and endpoints, its independent validation, and the proposed statistical analysis; efficiency gains depend on how well predictions perform in the intended trial population. Unlearn’s PROCOVA is one relevant methodology to investigate, rather than evidence that every “digital twin generator” is suitable for Phase 2 use.

Simcenter validates a digital twin by comparing its physics-based simulation outputs with measured test, sensor, and operational data from the real asset or process. Teams first define the model’s intended use and acceptance criteria, then collect representative measurements. Such as temperature, pressure, vibration, load, flow, or performance data. Across normal and edge-case operating conditions. They compare predicted versus observed behaviour, investigate deviations, and calibrate model parameters or data inputs before approving the model for its intended engineering decision.

For faster operational deployment, Simcenter RomAI can train reduced-order models from high-fidelity simulation and test data, then evaluate accuracy using target-versus-prediction, hyperplane, and time-based comparisons. Validated models can be exported into Simcenter Twin Activate, IoT environments, third-party platforms, or embedded systems.

After deployment, an executable digital twin can run alongside the physical system and ingest live IoT data for continuous monitoring and refinement. Validation is therefore an ongoing closed-loop process, not a one-time model check.

For life-sciences digital-twin evaluation, start with the vendor’s official trial or demonstration portal rather than downloading unverified software. Siemens offers Simcenter trials for simulation, system modelling, and engineering digital-twin workflows; its medical-device simulation trial provides 30-day browser-based access to licensed Simcenter software, sample files, and guided tutorials without a major local installation.

For clinical-development and in-silico trial use cases, consider vendors such as Dassault Systèmes and Medidata, but expect a guided demonstration, pilot, or commercial evaluation rather than a self-service download. Medidata positions virtual-twin technology for simulation-driven clinical development and in-silico trials, while Dassault Systèmes offers evaluation routes for its 3DEXPERIENCE platform.

Before beginning a trial, define one use case. Such as medical-device performance, manufacturing-process simulation, trial design, or patient-outcome modelling. And confirm data security, validation, integration, and intended-use requirements.

Yes, but the concept is still primarily a research and evaluation area, rather than evidence that AI-generated “virtual patients” can replace participants in conventional clinical trials. One emerging example is TWIN-GPT, a large-language-model approach that explores how patient-specific digital twins might be generated from clinical-trial and electronic-health-record data to model potential clinical trajectories.

The potential value is in supporting research tasks such as trial design, cohort exploration, scenario modelling, and hypothesis generation. However, a model that produces plausible patient trajectories does not by itself establish treatment efficacy, safety, causal effects, regulatory acceptability, or suitability for replacing a real control group. Clinical use requires independent validation, transparent performance assessment, privacy safeguards, defined intended use, and continued human and scientific oversight.

For a detailed, evidence-aware review of the research, limitations, and implications for clinical development, read: TWIN-GPT: Digital Twins for Clinical Trials via Large Language Model.

Digital twins can potentially reduce trial costs by improving statistical efficiency, allowing some studies to recruit fewer participants while maintaining statistical power. The ability to detect a treatment effect. In this setting, a digital twin is a model-generated forecast of a participant’s outcomes under placebo or standard care, based on their baseline characteristics. Those predictions can inform the analysis without replacing the randomised comparison.

For example, Unlearn reports that a retrospective analysis of a completed 513-participant ALS trial indicated that a comparable future study could maintain power with 92 fewer participants, translating into approximately $14 million in projected enrolment savings. This was a modelled saving, not a demonstrated reduction in that completed trial’s expenditure.

Regulatory acceptance also has boundaries. The EMA qualified PROCOVA, a prognostic covariate-adjustment methodology, for specified uses in Phase 2 and 3 trials with continuous outcomes. This is not blanket approval of every digital-twin model, trial design or cost-saving claim.

For sponsors, the practical question is whether reduced recruitment and participant-management costs exceed the costs of modelling, data preparation, validation and implementation. Request endpoint-specific evidence, realistic recruitment assumptions and a full budget comparison. A smaller projected sample does not automatically mean proportionately lower total costs or a shorter trial.